Maple 
Tesamorelin peptide Canada from Maple Research Labs provides 5mg of research-grade GHRH analog with verified 99.14% HPLC-UV purity and third-party COA testing.
Tesamorelin peptide Canada: a synthetic analog of growth hormone-releasing hormone (GHRH) consisting of 44 amino acids with a trans-3-hexenoic acid modification at the N-terminus. Available from Maple Research Labs at 5mg per vial with 99.14% HPLC-UV verified purity and batch-specific COA.
Product Specifications
- CAS Number: 218949-48-5
- Structure: Modified GHRH(1-44) analog
- Molecular Weight: Approximately 5135 Da
- Purity: 99.14% (HPLC-UV verified, this batch)
- Form: Lyophilized powder
- Quantity: 5mg per vial
Tesamorelin Peptide Canada Research Summary
Tesamorelin is a synthetic growth hormone-releasing hormone (GHRH) analog that stimulates the anterior pituitary to produce and release growth hormone through the GHRH receptor pathway. The tesamorelin peptide Canada product features the characteristic trans-3-hexenoic acid modification at the tyrosine-1 position, which confers increased resistance to enzymatic degradation compared to native GHRH(1-44).
Unlike direct growth hormone secretagogues that act on the GHSR (ghrelin receptor), tesamorelin operates through the GHRH receptor, stimulating physiological pulsatile GH release patterns. This distinction in mechanism is significant for neuroendocrine research, as GHRH-mediated and ghrelin-mediated GH release involve different signaling cascades and feedback mechanisms.
Mechanism of Action Research
Tesamorelin binds to the GHRH receptor (GHRHR) on somatotroph cells in the anterior pituitary gland. Receptor activation triggers adenylyl cyclase signaling, elevating intracellular cAMP levels and ultimately leading to GH gene transcription, synthesis, and secretion. Because it acts through the pituitary, GH release stays under the normal feedback controls of the GH axis, unlike exogenous GH, which bypasses the pituitary entirely.
The N-terminal hexenoic acid modification protects tesamorelin from dipeptidyl peptidase IV (DPP-IV) cleavage, which rapidly inactivates native GHRH by removing the N-terminal Tyr-Ala dipeptide. This structural modification extends the peptide’s biological half-life while preserving receptor binding affinity and selectivity.
GHRH analogs differ mainly in how their structure is protected from enzymatic breakdown, which changes how long they stimulate the GHRH receptor. Tesamorelin carries a trans-3-hexenoyl group on its full 44-residue sequence; CJC-1295 is a substituted GHRH(1-29) fragment, studied with and without a drug affinity complex (DAC). These structural differences make the compounds useful comparators in neuroendocrine receptor research.
Preclinical Research Summary
In non-clinical studies, tesamorelin (development code TH9507) was resistant to degradation by dipeptidyl peptidase IV and raised circulating growth hormone and IGF-1 levels in rats and dogs (Ferdinandi et al., 2007). In laboratory research it is used as a stabilised GHRH receptor agonist to study somatotroph signalling, cAMP-dependent GH synthesis and secretion, pulsatile release dynamics and regulation of the GH/IGF-1 axis.
All research applications of this product are for laboratory use only. Researchers should consult primary literature for experimental protocols.
References
Tesamorelin Peptide Canada Quality Assurance
Verified products of tesamorelin peptide Canada from Maple Research Labs undergoes independent third-party HPLC analysis confirming purity exceeding 98%+. Each order includes a batch-specific COA with retention time data, purity percentage, and measured fill accuracy against label claim. The N-terminal hexenoic acid modification requires specific analytical verification, which our third-party laboratory confirms for structural integrity on every production batch.
Storage and Handling
Store lyophilized at -20C. Reconstituted at 2-8C, use within 28 days. Avoid freeze-thaw cycles.
Shipping
Orders placed by 2 PM PT (Mon–Fri) ship the same business day, from BC with tracking. Temperature-controlled packaging included.
Certificate of Analysis (COA)
| Testing Laboratory | Independent third-party laboratory |
| Report Number | DBAV-TESA-5-062226 |
| Lot Number | 5815 |
| Purity (HPLC-UV) | 99.14% |
| Content / Fill Accuracy | 4.83mg measured / 5.00mg expected (96.6%) |
| Date Tested | July 9, 2026 |
| Download COA | Download Full COA (PDF) |
For research purposes only. Not for human consumption. Not for diagnostic or therapeutic use.
Related Research Articles
- HGH vs Tesamorelin: Research Comparison
- Ipamorelin vs Tesamorelin: Understanding the Differences
- Certificates of Analysis (COA) Documentation
- Browse All Research Peptides
Frequently Asked Questions
What is the CAS number for Tesamorelin?
The CAS registry number for Tesamorelin is 218949-48-5. It is a synthetic analog of growth hormone-releasing hormone (GHRH).
What is Tesamorelin purity at Maple Research Labs?
Report DBAV-TESA-5-062226 (lot 5815) tested at 99.14% purity by HPLC at an independent third-party laboratory.
How should Tesamorelin be stored?
Lyophilized: -20C. Tesamorelin is a 44-amino acid peptide and should be protected from repeated freeze-thaw cycles once reconstituted.
Related Research Peptides from Maple Research
Researchers may also be interested in CJC-1295 (No DAC), Ipamorelin 5MG, and CJC-1295/Ipamorelin Blend. All products include third-party purity verification. Orders placed by 2 PM PT (Mon–Fri) ship the same business day, from BC with tracking.
Join the research list
New arrivals, current pricing, and research breakdowns. New arrivals, current pricing, and research breakdowns. Unsubscribe anytime.
